Abstract

Rationale: The real-world REDES study reinforced mepolizumab effectiveness and safety in Severe Eosinophilic Asthma (SEA) patients in Spain. SEA patients in REDES achieved exacerbation reductions, OCS elimination, and symptom control. This post hoc analysis assessed if the blood eosinophil reduction achieved with mepolizumab treatment influences the clinical improvement with mepolizumab.

Methods: REDES was a retrospective, observational study of mepolizumab 100mg SC every 4 weeks in SEA patients in Spain. We report the outcomes at 12 months in SEA patients stratified by two groups: patients who achieved BEC <50 cells/µL and patients with BEC >50 and =100 cells/µL. Results are descriptive.

Results: At 12 months, 74 patients had 0-50 cells/µL and 107 had 50-100 cells/µL. In patients with 50-100 cells/µL, exacerbations were reduced by 81%, OCS were reduced by 68% and 48% of patients were OCS-free. In patients with 0-50 cells/µL, exacerbations were reduced by 75%, OCS were reduced by 39% and 39% of patients were OCS-free (p=ns). The changes in ACT score and pre-BD FEV₁ were similar between the two groups (Table).

Conclusions: Results from this analysis suggest that, after 12 months with an anti-IL-5 treatment, SEA patients with a BEC below 50 cells/µL do not have better outcomes than those with BECs reduced =100 cells/µL but maintained above 50 cells/µL.

Funding: GSK (GSK ID 213172)